What GLP-1 Is — and Why It Matters
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone secreted by intestinal L-cells in response to food intake. It plays a central role in metabolic regulation: stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and — critically — acting on the brain's appetite and satiety centers to reduce caloric intake. In people with obesity or metabolic dysfunction, this signaling system is often impaired, contributing to difficulty with appetite regulation and weight management.
GLP-1 receptor agonists are a class of medications that mimic the effects of this hormone by binding to and activating GLP-1 receptors throughout the body. What began as a treatment for type 2 diabetes has become one of the most significant pharmacological developments in obesity medicine in decades.
What Clinical Trials Show
The clinical evidence for GLP-1 receptor agonists in weight management is substantial. The STEP trials for semaglutide demonstrated average weight reductions of 15–17% of body weight over 68 weeks — a magnitude previously associated only with bariatric surgery. The SURMOUNT trials for tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even more pronounced effects, with some participants achieving 20–22% reductions in body weight.
Beyond weight, these medications have demonstrated meaningful improvements in metabolic markers: reduced fasting insulin and HOMA-IR, improved lipid profiles, lower blood pressure, and — in the SELECT trial for semaglutide — a significant reduction in major cardiovascular events in patients with established cardiovascular disease and overweight or obesity. The cardiovascular data in particular has reshaped how the field views these medications.
Who May Benefit
GLP-1 receptor agonists may be appropriate for patients with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity — including metabolic syndrome, type 2 diabetes, cardiovascular disease, or obstructive sleep apnea. Your physician may also consider them in the context of insulin resistance or significant difficulty with weight management despite lifestyle interventions. They are not appropriate for everyone, and individual medical history — including personal or family history of medullary thyroid carcinoma, pancreatitis, or certain gastrointestinal conditions — must be evaluated carefully.
Why Metabolic Labs Matter Before Starting
Before a physician considers whether a GLP-1 receptor agonist may be appropriate, a comprehensive metabolic baseline is essential. Fasting insulin, HOMA-IR, HbA1c, fasting glucose, lipid panel, hepatic markers, and hormonal status all inform the clinical picture. These medications work within a metabolic context — and understanding that context is foundational to evaluating candidacy, monitoring response, and adjusting the overall treatment strategy over time.
The Role of Physician Oversight and Monitoring
GLP-1 receptor agonists are prescription medications that require active physician oversight. Common side effects include nausea, vomiting, and gastrointestinal discomfort — typically dose-dependent and most pronounced during dose escalation. Ongoing monitoring of metabolic markers, nutritional status, and lean muscle mass is important, as rapid weight loss without adequate protein intake and resistance training can result in significant muscle loss alongside fat reduction.
At QIM Health, our approach to metabolic health begins with a comprehensive assessment of the factors driving weight and metabolic dysfunction — before discussing any specific intervention. The goal is not a medication prescription but a data-driven understanding of what your biology needs.